Ludiomil (maprotiline) is a small molecule pharmaceutical. Maprotiline was first approved as Ludiomil on 1982-01-01. It is used to treat bipolar disorder, bulimia, cocaine-related disorders, duodenal ulcer, and dysthymic disorder amongst others in the USA. The pharmaceutical is active against sodium-dependent noradrenaline transporter. In addition, it is known to target G protein-activated inward rectifier potassium channel 2, transient receptor potential cation channel subfamily M member 3, and G protein-activated inward rectifier potassium channel 4.
|Indication||bipolar disorder, bulimia, cocaine-related disorders, duodenal ulcer, dysthymic disorder, enuresis, pain, panic disorder|